

**TDMS No.** 20310 - 01

**Test Type:** 26-39 WEEKS

**Route:** GAVAGE

**Species/Strain:**

MICE/C3B6F1-+/Trp53(tm1Brd)

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

3'-Azido-3'-deoxythymidine (AZT)

**CAS Number:** 30516-87-1

**Date Report Requested:** 07/22/2009

**Time Report Requested:** 11:47:11

**First Dose M/F:** NA / 11/18/04

**Lab:** NCTR

**C Number:**

C20310C

**Lock Date:**

12/01/2008

**Cage Range:**

ALL

**Date Range:**

ALL

**Reasons For Removal:**

ALL

**Removal Date Range:**

ALL

**Treatment Groups:**

Include 612 Vehicle 6 mo F

Include 615 AZT 120 6 mo F

**Study Gender:**

Female

**TDMSE Version:**

2.1.0

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F
<b>Disposition Summary</b>		
Animals Initially in Study	27	26
Early Deaths		
Moribund Sacrifice	1	
Natural Death	1	
Survivors		
Moribund Sacrifice	1	
Terminal Sacrifice	24	26
Animals Examined Microscopically	27	26
<b>ALIMENTARY SYSTEM</b>		
Esophagus	(23)	(25)
Adventitia, Foreign Body	1 (4%)	
Adventitia, Necrosis	1 (4%)	
Gallbladder	(24)	(25)
Intestine Large, Cecum	(26)	(26)
Hyperplasia, Lymphoid		2 (8%)
Intestine Large, Rectum	(26)	(26)
Intestine Small, Ileum	(26)	(26)
Liver	(26)	(26)
Infiltration Cellular, Lymphocyte		1 (4%)
Inflammation, Chronic Active	3 (12%)	2 (8%)
Tension Lipidosis	1 (4%)	3 (12%)
Vacuolization Cytoplasmic	1 (4%)	1 (4%)
Pancreas	(26)	(26)
Infiltration Cellular, Lymphocyte		1 (4%)
Inflammation, Chronic Active		1 (4%)
Salivary Glands	(26)	(26)
Infiltration Cellular, Lymphocyte	14 (54%)	7 (27%)
Stomach, Glandular	(26)	(26)
<b>CARDIOVASCULAR SYSTEM</b>		
Heart	(26)	(26)
Cardiomyopathy	1 (4%)	
Pericardium, Inflammation, Chronic	1 (4%)	
Pericardium, Inflammation, Chronic Active		1 (4%)
Pericardium, Mineralization		1 (4%)

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F
<b>ENDOCRINE SYSTEM</b>		
Adrenal Cortex	(26)	(26)
Accessory Adrenal Cortical Nodule	1 (4%)	1 (4%)
Vacuolization Cytoplasmic	2 (8%)	
Subcapsular, Hyperplasia	23 (88%)	24 (92%)
Adrenal Medulla	(26)	(26)
Parathyroid Gland	(22)	(21)
Infiltration Cellular, Lymphocyte	1 (5%)	
Pituitary Gland	(26)	(26)
Thyroid Gland	(26)	(25)
Cyst	1 (4%)	
Infiltration Cellular, Lymphocyte	1 (4%)	1 (4%)
<b>GENERAL BODY SYSTEM</b>		
Tissue NOS	(0)	(1)
Abscess		1 (100%)
<b>GENITAL SYSTEM</b>		
Ovary	(26)	(26)
Cyst		1 (4%)
Uterus	(26)	(26)
Endometrium, Hyperplasia, Cystic	1 (4%)	1 (4%)
Lumen, Dilatation	2 (8%)	2 (8%)
Vagina	(27)	(26)
<b>HEMATOPOIETIC SYSTEM</b>		
Bone Marrow	(26)	(26)
Myeloid Cell, Hyperplasia	3 (12%)	2 (8%)
Lymph Node	(3)	(1)
Mediastinal, Hyperplasia, Lymphoid	2 (67%)	
Mediastinal, Infiltration Cellular, Plasma Cell	1 (33%)	
Lymph Node, Mandibular	(26)	(25)
Hyperplasia, Lymphoid	3 (12%)	2 (8%)
Lymph Node, Mesenteric	(24)	(25)
Hyperplasia, Lymphoid	7 (29%)	11 (44%)
Spleen	(26)	(26)
Depletion Lymphoid	1 (4%)	
Hematopoietic Cell Proliferation	3 (12%)	2 (8%)
Hyperplasia, Lymphoid		2 (8%)

TDMS No. 20310 - 01  
Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Date Report Requested: 07/22/2009

Time Report Requested: 11:47:11

First Dose M/F: NA / 11/18/04

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F
Thymus	(26)	(26)
Hyperplasia, Lymphoid	3 (12%)	2 (8%)
Hyperplasia, Plasma Cell	1 (4%)	
Necrosis	1 (4%)	
Adventitia, Inflammation, Chronic	1 (4%)	
Epithelial Cell, Hyperplasia	1 (4%)	
<b>INTEGUMENTARY SYSTEM</b>		
Mammary Gland	(24)	(24)
Skin	(26)	(26)
<b>MUSCULOSKELETAL SYSTEM</b>		
None		
<b>NERVOUS SYSTEM</b>		
Brain, Cerebrum	(26)	(26)
Cyst Epithelial Inclusion	1 (4%)	
<b>RESPIRATORY SYSTEM</b>		
Lung	(26)	(26)
Abscess	2 (8%)	
Infiltration Cellular, Lymphocyte	1 (4%)	
Inflammation, Chronic Active		1 (4%)
Mediastinum, Inflammation, Chronic Active		1 (4%)
Mediastinum, Mineralization		1 (4%)
Mediastinum, Necrosis	1 (4%)	
<b>SPECIAL SENSES SYSTEM</b>		
Harderian Gland	(26)	(26)
Infiltration Cellular, Lymphocyte	1 (4%)	
<b>URINARY SYSTEM</b>		
Kidney	(26)	(26)
Infiltration Cellular, Lymphocyte	8 (31%)	3 (12%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 01

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

3'-Azido-3'-deoxythymidine (AZD)

CAS Number: 30516-87-1

Date Report Requested: 07/22/2009

Time Report Requested: 11:47:11

First Dose M/F: NA / 11/18/04

Lab: NCTR

---

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F
Inflammation, Chronic Active	1 (4%)	
Urinary Bladder	(26)	(26)
Infiltration Cellular, Lymphocyte	3 (12%)	1 (4%)

---

\*\*\* END OF REPORT \*\*\*